Request Demo

Last update 15 May 2025

Chlorthalidone

Last update 15 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryChlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys. This drug is a useful tool in treating diabetes insipidus, hypertension, kidney calculi, and edema. Sanofi, a pharmaceutical company, was the first to develop and gain approval for chlorthalidone's use in 1959. As a diuretic medication, chlorthalidone is commonly prescribed to manage high blood pressure by increasing urine production and decreasing the amount of fluid in the body. Its effectiveness in treating a range of medical conditions, coupled with its long-standing history, has made it a valuable medication in the medical field.

Drug Type

Small molecule drug

Synonyms

1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline, 1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide

+ [17]

Target

NCC

Action

inhibitors

Mechanism

NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

Diabetes InsipidusEdemaHypertension+ [1]

Inactive Indication-

Originator Organization

Sanofi

Active Organization

Chengdu First Pharmaceutical Co. Ltd.PRM Pharma, LLC

Casper Pharma LLC

Inactive Organization

Sanofi-Aventis U.S. LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (07 Apr 1960),

Hypertension

Regulation-

Structure/Sequence

Molecular FormulaC14H11ClN2O4S

InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N

CAS Registry77-36-1

Clinical Trials associated with Chlorthalidone

NCT02483936

/ Not yet recruitingPhase 3

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Start Date01 Dec 2024

Sponsor / Collaborator

EMS SA (Brazil)

NCT02493322

/ Not yet recruitingPhase 3

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Start Date01 Dec 2024

Sponsor / Collaborator

EMS SA (Brazil)

NCT06111885

/ RecruitingPhase 2

Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

Start Date01 Oct 2024

Sponsor / Collaborator

Insel Gruppe AG

100 Clinical Results associated with Chlorthalidone

100 Translational Medicine associated with Chlorthalidone

100 Patents (Medical) associated with Chlorthalidone

2,757

Literatures (Medical) associated with Chlorthalidone

01 May 2025·Journal of Clinical Hypertension

Thiazide‐Associated Hyponatremia: A Retrospective Cohort Study Comparing Hydrochlorothiazide Versus Indapamide Versus Chlorthalidone

Article

Author: Kojecký, Vladimír ; Ponížil, Petr ; Šálek, Tomáš ; Vodička, Martin ; Klhůfek, Josef ; Fojtík, Petr ; Ryšavý, Ilja

ABSTRACT:

Hyponatremia is a crucial complication of therapy with thiazide diuretics. This study compares the epidemiological and biochemical profiles and hospital course of patients using hydrochlorothiazide (HCTZ), indapamide (INDA), and chlorthalidone (CTD) admitted with thiazide‐associated hyponatremia (TAH). Data were obtained retrospectively from the hospital's digital registries. The epidemiological and biochemical parameters between the HCTZ, INDA, and CTD groups were compared. The correlation between dose and biochemical parameters in each group was performed. The thiazide groups without diuretic co‐medication were compared (HCTZ vs. INDA), and the correlation between dose and biochemical parameters in each group was examined. A comparison of the HCTZ (n = 135), INDA (n = 125), and CTD (n = 27) groups identified differences in serum potassium (s‐K; p = 0.03). The hyponatremia correction rate was slower in the CTD group at 96 h after admission (p < 0.001). After the exclusion of diuretic co‐medication, the HCTZ group (n = 64/135) showed a higher prevalence of ARBs, s‐K (both p < 0.001), and a lower median (IQR) equipotent dose (12.5 (o) mg vs. 2.5 (1.2) mg), prevalence of ACE‐I (p < 0.001), and eGFR (p = 0.03), when compared to the INDA group (n = 109/125). In conclusion, except for s‐K, we observed no significant difference in biochemical and epidemiological profiles between HCTZ, INDA, and CTD. After excluding the influence of other diuretics, we observed higher s‐K in the HCTZ group compared to the INDA group, potentially explained by the lower equipotent dose of HCTZ. The CTD group showed a statistically significant trend of slower hyponatremia correction.

01 Apr 2025·JOURNAL OF CARDIAC FAILURE

Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment) Study

Article

Author: Verbeeck, Johan ; Verbrugge, Frederik H ; Verbrugge, Frederik H. ; Wilson Tang, W.H. ; Vanhentenrijk, Simon ; Vandoren, Vincent ; L'Hoyes, Wouter ; Choustoulakis, Eleftherios ; L'hoyes, Wouter ; Roosens, Bram ; Tang, W H Wilson ; Kalpakos, Theodoros ; Braeckeveldt, Laura ; Verwerft, Jan

AIMS:

To evaluate whether early-combination diuretic therapy guided by serial post-diuretic urine sodium concentration (UNa⁺) assessments in acute heart failure (AHF) facilitates safe and effective decongestion.

METHODS:

The Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment (DECONGEST) study is a pragmatic, 2-center, randomized, parallel-arm, open-label study aiming to enroll 104 patients with AHF and clinically evident fluid overload requiring treatment with intravenous loop diuretics. Patients are randomized to receive standard of care or a bundled approach comprising: (1) systematic post-diuretic UNa⁺ assessments until successful decongestion, defined as no remaining clinical signs of fluid overload with a post-diuretic UNa⁺ ≤ 80 mmol/L; (2) thrice-daily intravenous loop diuretic bolus therapy, with dosing according to estimated glomerular filtration rate; (3) upfront use of intravenous acetazolamide (500 mg once daily [OD]); and (4) full nephron blockade with high-dose oral chlorthalidone (100 mg OD) and intravenous canreonate (200 mg OD) for diuretic resistance, defined as persisting signs of fluid overload with a post-diuretic UNa⁺ ≤ 80 mmol/L. The primary endpoint of the DECONGEST study is a hierarchical composite of (1) survival at 30 days; (2) days alive and out of hospital or care facility up to 30 days; and (3) greater relative decrease in natriuretic peptide levels from baseline to day 30.

CONCLUSION:

The DECONGEST study aims to determine whether an intensive diuretic regimen focused on early combination therapy, guided by serial post-diuretic UNa+ assessments, safely enhances decongestion, warranting further evaluation in a larger trial powered for clinical events.

01 Mar 2025·AMERICAN JOURNAL OF MEDICINE

Chlorthalidone as Secondary Treatment in HFpEF?

Review

Author: Gelfman, Daniel M. ; Gelfman, Daniel M

This review addresses important issues that face practitioners today concerning the treatment of heart failure with preserved ejection fraction (HFpEF). It points out how the accepted efficacy of HFpEF medication treatment has changed. Medications are now recommended for use in HFpEF that have diuretic properties and are significant because of a reduction in the frequency of the development of heart failure (not mortality). This heart failure incidence reduction appears predictable and is valuable, but it raises the question of the use of chlorthalidone in the treatment of HFpEF. Chlorthalidone has previously been demonstrated to reduce heart failure incidence in the treatment of hypertensive patients, which is a similar patient population. Chlorthalidone, possibly with a generic mineralocorticoid antagonist, could be an acceptable low-cost alternate therapy as secondary treatment for HFpEF. Of course, chlorthalidone does not have the other theoretic benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitors or finerenone. It would be helpful if this was discussed in the upcoming HFpEF guidelines, especially for use in patients who cannot afford or tolerate the new HFpEF medications.

News (Medical) associated with Chlorthalidone

06 May 2025

·www.prnewswire.com

FDA Approves New, Low-Dose Chlorthalidone for the Treatment of Hypertension in Adults: HemiClor™ (12.5 mg chlorthalidone)

WEST CONSHOHOCKEN, Pa., May 6, 2025 /PRNewswire/ -- PRM Pharma, LLC today announced the U.S. Food and Drug Administration (FDA) approval of HemiClor (12.5 mg chlorthalidone) tablets for the treatment of hypertension in adults, to lower blood pressure. Chlorthalidone, a thiazide-like diuretic, has been studied extensively over several decades in the treatment of hypertension. It is recognized in the 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults as the preferred diuretic based on its prolonged half-life and evidence of cardiovascular outcome benefits.1 Landmark studies such as the ALLHAT and SHEP trials, sponsored by the National Heart, Lung, and Blood Institute, demonstrated that stepped-care treatment strategies—which often began with 12.5 mg of chlorthalidone—were effective in reducing the risk of cardiovascular events.2,3 These findings support the use of 12.5 mg as the recommended starting dose in current hypertension treatment guidelines, either to initiate antihypertensive therapy or to serve as add-on therapy when additional blood pressure reduction is needed.1,4 HemiClor now provides U.S. patients and healthcare professionals access to a 12.5 mg chlorthalidone tablet formulation that aligns with guideline recommendations. Until now, only higher-dose chlorthalidone tablets (25 mg and 50 mg) have been available in the U.S. This new low-dose option may help clinicians better individualize therapy and potentially reduce the risk of dose-related side effects. As noted in the approved prescribing information, metabolic adverse effects such as hypokalemia and hyperuricemia are dose-related; thus, a lower starting dose may help mitigate these risks when initiating treatment.5 "Chlorthalidone has played a key role in hypertension treatment strategies for decades," said William B. White, M.D., Professor Emeritus at the University of Connecticut School of Medicine and past president of the American Society of Hypertension. "Having access to a 12.5 mg dose in the U.S. may offer clinicians additional flexibility when initiating therapy and aligns with current treatment recommendations for many adult patients with stage 1 or stage 2 hypertension." Joseph T. McDevitt, President and CEO of PRM Pharma, LLC, added, "We are proud to introduce HemiClor as a new treatment option for adults with hypertension. Our mission is to address unmet clinical needs by developing low-dose pharmaceutical products that support evidence-based care. Lower effective doses may offer a more individualized approach to initiating therapies, particularly for elderly patients who are more susceptible to dose-related adverse effects." HemiClor (12.5 mg chlorthalidone tablets) is expected to be available in pharmacies nationwide beginning in May 2025. Indication and Usage HemiClor (chlorthalidone) is indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been demonstrated in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including chlorthalidone. Important Safety Information Contraindications: HemiClor is contraindicated in patients with anuria or known hypersensitivity to chlorthalidone or sulfonamide-derived drugs. Adverse Reactions: The most common adverse reactions observed with chlorthalidone include electrolyte imbalance (particularly hypokalemia), dizziness, and gastrointestinal discomfort. Monitoring: Periodic monitoring of serum electrolytes is recommended. Chlorthalidone may increase blood sugar levels, affect diabetes control, and cause changes in the need for diabetes medication Drug Interactions: Chlorthalidone may potentiate the effects of other antihypertensive agents and may interact with lithium, antidiabetics, or NSAIDs. These are not all the possible side effects of Chlorthalidone. Please see the full Prescribing Information, available at , for complete efficacy and important safety Information. About PRM Pharma, LLC PRM Pharma, LLC is a privately held specialty pharmaceutical company based in Pennsylvania, focused on developing low-dose therapies to support clinical practice guidelines and improve patient care. Media Inquiries: PRM Pharma, LLC – Media Relations Email: [email protected] Website: To report suspected adverse reactions, contact PRM Pharma at [email protected] or the FDA at or 1-800-FDA-1088. References Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066 ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Patients with Isolated Systolic Hypertension. JAMA. 1991;265(24):3255–3264. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA. 2014;311(5):507–520. doi:10.1001/jama.2013.284427 HemiClor™ Prescribing Information. PRM Pharma, LLC. 2025. PRM_PR_001 SOURCE PRM Pharma, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

16 May 2024

·www.prnewswire.com

New Analysis on Hypertension Treatment to be Presented as Late-Breaking Research at National Kidney Foundation Spring Clinical Meetings

LONG BEACH, Calif., May 16, 2024 /PRNewswire/ -- A new analysis of a study comparing two commonly used medications, chlorthalidone (CTD) and hydrochlorothiazide (HCTZ), is set to be presented as a late-breaking presentation at the annual 2024 National Kidney Foundation Spring Clinical Meetings. Continue Reading The study, titled "Treatment with Chlorthalidone vs Hydrochlorothiazide and Renal Outcomes: The Diuretic Comparison Project (DCP)," conducted by a team of distinguished researchers from various institutions and led by Areef Ishani, MD MS, Minneapolis VA Health Care System Primary Care and Specialty Care Integrated Care Community (ICC) Director and Professor of Medicine, University of Minnesota provides crucial insights into the impact of these medications on renal health in hypertensive patients. New study comparing two commonly used medications set to be shared as a late-breaking presentation at NKF's Conference. Post this Hypertension, or high blood pressure, is a significant risk factor for the development and progression of chronic kidney disease (CKD). Previous research had hinted at potential differences in kidney outcomes between chlorthalidone and hydrochlorothiazide. This new study followed more than 12,000 participants for an average of 3.9 years. The study found no significant disparity in renal outcomes between patients treated with chlorthalidone and those treated with hydrochlorothiazide. Specifically, there was no marked difference observed in the primary composite renal outcome, including doubling of serum creatinine, a significant drop in estimated glomerular filtration rate (eGFR), or kidney failure requiring treatment (KFRT), between the two treatment groups. Furthermore, the study revealed that the total slope of eGFR change and the incidence of chronic kidney disease (CKD) were comparable between patients receiving chlorthalidone and hydrochlorothiazide, suggesting similar efficacy in preserving kidney function. The findings offer reassurance that both chlorthalidone and hydrochlorothiazide may be equally effective choices for managing hypertension without compromising renal health. About NKF Spring Clinical Meetings For the past 32 years, nephrology healthcare professionals from across the country have come to NKF's Spring Clinical Meetings to learn about the newest developments related to all aspects of nephrology practice; network with colleagues; and present their research findings. The NKF Spring Clinical Meetings is designed for meaningful change in the multidisciplinary healthcare teams' skills, performance, and patient health outcomes. It is the only conference of its kind that focuses on translating science into practice for the entire healthcare team. About Kidney Disease In the United States, more than 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don't know they have it. About 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at increased risk for developing the disease. Black or African American people are about four times as likely as White people to have kidney failure. Hispanics experience kidney failure at about double the rate of White people. About NKF Professional Memberships Healthcare professionals can join NKF to receive access to tools and resources for both patients and professionals, discounts on professional education, and access to a network of thousands of individuals who treat patients with kidney disease. About the National Kidney Foundation The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. NKF Website Instagram Facebook X SOURCE The National Kidney Foundation

Clinical Study

15 Dec 2022

·www.sciencedaily.com

New study method finds two blood pressure drugs equally effective

A clinical trial found that two first-line treatments for high blood pressure were equally effective. A large VA clinical trial found that the blood pressure drug chlorthalidone (CTD) was not superior to hydrochlorothiazide (HCTZ) for the prevention of cardiovascular disease or non-cancer death. Both drugs are in a class of medications called thiazide diuretics, commonly known as water pills. They are used to help the body rid itself of excess fluid, which can lower blood pressure. The study was a first-of-its-kind pragmatic trial that was embedded in usual clinical care. As part of VA's clinical trials enterprise, it allowed participation from across the country with no additional staff. Also, all study procedures were done as part of routine clinical care. There was no additional burden placed on Veterans who participated in the study, including no extra visits. "Because of the number of Veterans VA cares for and our systemwide electronic medical record, we were able to embed this massive clinical trial within day-to-day care without any additional burden to the thousands of Veterans who volunteered for this study," said Rachel Ramoni, VA's chief research and development officer. "The result is important evidence of how these widely-used medications work in the real world." Current clinical guidelines say that CTD may be more effective than HCTZ to lower blood pressure, but this recommendation is unsupported by direct evidence. Both medications have been used for more than 50 years and each is considered a first-line treatment for hypertension. "In 2020, Medicare reported that approximately 1.5 million people were prescribed CTD compared to 11.5 million prescribed HCTZ, despite guideline recommendations," said principal investigator Dr. Areef Ishani, director of the Minneapolis VA Health Care System's Primary Care and Specialty Care Integrated Care Community. "This discrepancy between clinical guidelines and real-world usage is possibly related to the belief that CTD has a greater risk of adverse effects without clear evidence for differences in cardiovascular outcomes." The Diuretic Comparison Project (CSP 597) is a large pragmatic clinical trial that was conducted at 537 VA medical centers and community clinics in the U.S. The trial enrolled more than 4,000 providers and 13,500 Veterans with high blood pressure who were taking HCTZ at baseline. Study participants were randomized to stay on their current dose of HCTZ or take an equivalent dose of CTD. Ninety-five percent of study participants were taking a lower dose of HCTZ, so the main study comparison was 12.5 mg CTD to 25 mg HCTZ. The team found no difference between the two drugs, at these lower doses, for the prevention of cardiovascular disease or non-cancer death, which included heart attack, stroke, heart failure, or lack of blood flow requiring medical intervention. There was a slight increase in the risk for low potassium in the CTD group, which quickly resolved with potassium supplements. "We were able to compare two commonly prescribed generic drugs using a low-cost methodology," said Ishani. "This trial has shown that large, embedded trials are operationally feasible. They can be incorporated into the clinical workflow of providers by leveraging the electronic health record and other existing infrastructure." The study was funded by the VA Cooperative Studies Program. The study results were published online December 14, 2022, by the New England Journal of Medicine.

Clinical ResultAHAClinical Study

100 Deals associated with Chlorthalidone

External Link

KEGG	Wiki	ATC	Drug Bank
D00272	Chlorthalidone	C03BA04	DB00310

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Insipidus	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Edema	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Nephrolithiasis	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Hypertension	United States	Sanofi-Aventis U.S. LLC	07 Apr 1960

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02841280 (CLICK, Pubmed)	Phase 2	Chronic Kidney Diseases 24-hour urinary sodium \| aldosterone \| plasma renin ... View more	160	Chlorthalidone	wavmqfgbwa(chnxjitngi) = rcrvshrwcn bhfunabgpb (sxmgzsrjhh, 25.4 - 57.4) View more	Positive	12 Jun 2024
ESH2024	Not Applicable	Coronary Artery Disease \| Essential Hypertension	-	Metoprolol + Telmisartan + Chlorthalidone	qdttdqudzr(yfqepvomdy) = hypotension being most common qucipmwkqn (mzyithyqdi )	Positive	01 May 2024
NCT02665117 (CTgov)	Not Applicable	Hypertension	61	Potassium Magnesium Citrate (KMgCit)+chlorthalidone (KMgCit + Chlorthalidone)	xfjkbmqzvl(vvmxqlvbuf) = busuoipktt wjqqihllid (vnmooxjwwg, 13.3) View more	-	25 Oct 2023
				Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone)	xfjkbmqzvl(vvmxqlvbuf) = zmjaympnsk wjqqihllid (vnmooxjwwg, 9.9) View more
SAT036 (ENDO2023)	Not Applicable	Diabetes Mellitus, Type 2	1	Chlorthalidone 25mg daily	oixmlojowl(bpbhxglkcl) = acidosis resolved within 24 hours with IV fluid resuscitation and Insulin drip on DKA protocol cqcbzwcyfq (dmlrtpicga ) View more	Negative	05 Oct 2023
				Metformin 500mg twice daily
NCT02841280 (CLICK, CTgov)	Phase 2	Hypertension \| Chronic Kidney Diseases	160	Chlorthalidone (Chlorthalidone)	jqcwrmgphg(lskfxjlxcj) = ojomznxabr zmxhtyiklu (xmrhwulmhx, wquowtbvfp - vpyhljsuik) View more	-	31 Mar 2022
				Placebo (Placebo)	jqcwrmgphg(lskfxjlxcj) = lyrjdrdzem zmxhtyiklu (xmrhwulmhx, mruqrwugsf - taepfphakh) View more
NCT02841280 (Pubmed \| N Engl J Med) Manual	Phase 2	Hypertension \| Chronic Kidney Diseases	160	Chlorthalidone	omfdhdxqof(udvrwsplvw) = ehtddzerxq ykcxbejvci (unzuwydrna, -13.9 to -8.1)	Positive	05 Nov 2021
				Placebo	omfdhdxqof(udvrwsplvw) = saagzzomiv ykcxbejvci (unzuwydrna, -3.5 to 2.5)
ESH2021	Not Applicable	Heart failure with normal ejection fraction \| Hypertension	-	Fixed-dose combination AZL-M/CLD	ehygvxengf(dfxwrqrsdz) = koccoetqwo rzovolzpme (jsvtefoqmo, 8.7 - 12.3)	Positive	01 Apr 2021
				Non-fixed-dose combinations of iACE/ARB and thiazide/thiazide-like diuretics	ehygvxengf(dfxwrqrsdz) = ljjdzlzfqe rzovolzpme (jsvtefoqmo, 9.2 - 12.8)
NCT03325114 (CTgov)	Phase 2	Diabetes Mellitus, Type 1 \| Hypercalciuria	1	chlorthalidone	fdopgfxxnt(clrwwuudxj) = ictwhoagbj ohzgtkvgmf (sptwtmahuc, qahslqkshi - ismejncphw) View more	-	05 Jan 2021
HEBE Trial (ASN2020)	Phase 4	Chronic Kidney Diseases	-	Bumetanide 2 mg BID + Chlorthalidone 50 mg BID	fqqnbgreey(oljlctdrkq) = vnoukbklgb jmaocgbftc (gasyrqkamg, 10.7) View more	Positive	19 Oct 2020
				Bumetanide 2 mg BID + Placebo	fqqnbgreey(oljlctdrkq) = vuktuzajwl jmaocgbftc (gasyrqkamg, 11.9) View more
NCT04393493 (CTgov)	Phase 2	Cardio-Renal Syndrome	80	Furosemide (Stepped Furosemide)	eaqwsrdpim = svyhtvrbrk iayqtgfjpf (kywjkpzmxx, vgwrpngtca - xbvewdwdmg) View more	-	14 Sep 2020
				Spironolactone+Furosemide+Chlortalidone (Diuretics Combined)	eaqwsrdpim = kbztananod iayqtgfjpf (kywjkpzmxx, rihxvqbtwh - joajligdrn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis